{"id":"zactima","rwe":[],"tags":[],"phase":"discontinued","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":["Breastfeeding (mother)","Cerebral ischemia","Congenital long QT syndrome","Heart failure","Hypertensive disorder","Hypocalcemia","Hypokalemia","Hypomagnesemia","Hypothyroidism","Impaired renal function disorder","Interstitial lung disease","Posterior reversible encephalopathy syndrome","Pregnancy, function","Prolonged QT interval","Severe diarrhea","Significant Bleeding","Torsades de pointes"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"discontinued","trials":["NCT00496275","NCT00481845","NCT00410189","NCT00508001","NCT00752986","NCT00312377","NCT00753675","NCT00533169","NCT00811369","NCT00450138","NCT00732745","NCT00252746","NCT00445549","NCT00822887","NCT00777179","NCT01183559","NCT00566995","NCT00496509","NCT00472017","NCT00681798","NCT00496665","NCT00613223","NCT00358956","NCT02530411","NCT01582191","NCT00410761","NCT00364351","NCT00613054","NCT00459043","NCT01004419","NCT00862836","NCT00745732","NCT00807170","NCT00507091","NCT00494481","NCT00551096","NCT00506051","NCT00686036","NCT00659438","NCT00454116","NCT00459121","NCT00503711","NCT00441142","NCT00498797","NCT00597116","NCT00499850","NCT00880334","NCT00514046","NCT00923247","NCT00660725"],"aliases":["Caprelsa","ZD6474","Vandetanib"],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"brandName":"Zactima","companyId":"barbara-ann-karmanos-cancer-institute","ecosystem":[],"mechanism":{"target":"AarF domain-containing protein kinase 4, Bone morphogenetic protein receptor type-1B, Chaperone activity of bc1 complex-like, mitochondrial","novelty":"","modality":"Small molecule","drugClass":"","explanation":"","oneSentence":"","technicalDetail":""},"commercial":null,"references":[],"biosimilars":[],"companyName":"Barbara Ann Karmanos Cancer Institute","competitors":[],"dataSources":[{"url":"https://clinicaltrials.gov","name":"ClinicalTrials.gov","fields":["trialDetails","trials"],"retrievedDate":"2026-04-07"},{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"Zactima","indications":{"approved":[{"name":"Carcinoma of thyroid","diseaseId":"carcinoma-of-thyroid","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Medullary thyroid carcinoma","diseaseId":"medullary-thyroid-carcinoma","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT00496275","phase":"Phase 1","title":"A Phase I, Open Label Study to Assess the Safety and Tolerability of ZD6474 (ZACTIMA) in Combination With Vinorelbine (Navelbine) or Gemcitabine (Gemzar) Plus Cisplatin as First Line Therapy in Patien","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","isPivotal":false,"enrollment":17,"indication":"Non Small Cell Lung Cancer","completionDate":"2007-05"},{"nctId":"NCT00481845","phase":"Phase 2","title":"Randomized Phase 2 Trial of Anastrozole Combined With Novel Agent ZD6474 in the Neoadjuvant Treatment of Postmenopausal Patients With Hormone Receptor-Positive Breast Cancer","status":"TERMINATED","sponsor":"Stanford University","isPivotal":false,"enrollment":1,"indication":"Breast Cancer","completionDate":"2009-12"},{"nctId":"NCT00410189","phase":"Phase 2","title":"A Phase II, Open Label Study of ZD6474 in Previously Treated Subjects With Advanced Non-Small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","isPivotal":false,"enrollment":54,"indication":"Lung Cancer","completionDate":"2013-03"},{"nctId":"NCT00508001","phase":"Phase 2","title":"A Randomised, Double-blind, Parallel Group, Multi-centre, Phase II Study to Assess the Efficacy and Safety of Best Support Care (BSC) Plus ZD6474(Vandetanib) 300 mg, BSC Plus ZD6474(Vandetanib) 100 mg","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","isPivotal":false,"enrollment":67,"indication":"Carcinoma, Hepatocellular","completionDate":"2009-06"},{"nctId":"NCT00752986","phase":"Phase 2","title":"A Randomized,Double-blind,Parallel-group,Multicentre,Phase II Study to Evaluate the Safety and Pharmacological Activity of the Combination of Vandetanib (100 or 300 MG/Daily or Placebo)With Fulvestran","status":"TERMINATED","sponsor":"Genzyme, a Sanofi Company","isPivotal":false,"enrollment":39,"indication":"Breast Cancer","completionDate":"2013-09"},{"nctId":"NCT00312377","phase":"Phase 3","title":"A Phase III, Randomized, Double-Blinded, Multi-Center, Study to Assess the Efficacy of Docetaxel (TAXOTERE™) in Combination With ZD6474 (ZACTIMA™) Versus Docetaxel (TAXOTERE™) With Placebo in Subjects","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","isPivotal":true,"enrollment":1690,"indication":"Non-small Cell Lung Cancer, Lung Cancer","completionDate":"2014-03"},{"nctId":"NCT00753675","phase":"Phase 2","title":"A Randomized, Multicentre, Phase II, Parallel-Group Trial of Vandetanib Monotherapy or Vandetanib in Combination With Gemcitabine Versus Gemcitabine Plus Vandetanib Matching Placebo in Subjects With A","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","isPivotal":false,"enrollment":174,"indication":"Biliary Tract Cancer, Gallbladder Cancer","completionDate":"2012-09"},{"nctId":"NCT00533169","phase":"Phase 1","title":"A Phase I Study of ZD6474 (Zactima) Alone and in Combination With Retinoic Acid in Relapsed and Refractory Pediatric Neuroblastoma","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","isPivotal":false,"enrollment":10,"indication":"Neuroblastoma","completionDate":"2011-02"},{"nctId":"NCT00811369","phase":"Phase 2","title":"A Phase II, Multi-Centre, Randomized, Double-blind Trial to Evaluate the Therapeutic Benefit of Fulvestrant in Combination With ZACTIMA or Fulvestrant Plus Placebo in Postmenopausal Women With Bone On","status":"COMPLETED","sponsor":"Ontario Clinical Oncology Group (OCOG)","isPivotal":false,"enrollment":126,"indication":"Metastatic Breast Cancer","completionDate":"2013-08"},{"nctId":"NCT00450138","phase":"Phase 1","title":"An Open Label Phase 1 Study to Assess the Maximum Tolerated Dose of ZACTIMA™ Given Concomitantly With Weekly Cisplatin Chemotherapy and Radiation Therapy in Patients With Previously Untreated, Unresec","status":"COMPLETED","sponsor":"Sanofi","isPivotal":false,"enrollment":48,"indication":"Head and Neck Cancer","completionDate":"2011-11"},{"nctId":"NCT00732745","phase":"Phase 1","title":"Phase I/II Study of the Combination of Oxaliplatin / Docetaxel and ZACTIMA for the Treatment of Advanced Cancers of the Esophagus and Gastroesophageal Junction","status":"TERMINATED","sponsor":"Case Comprehensive Cancer Center","isPivotal":false,"enrollment":9,"indication":"Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer","completionDate":""},{"nctId":"NCT00252746","phase":"Phase 2","title":"A Randomised, Double-blind, Parallel-group, Dose Finding Study to Assess the Efficacy and Safety of ZD6474 in Patients With Advanced, Metastatic, or Recurrent NSCLC Who Have Failed Previous Chemothera","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","isPivotal":false,"enrollment":53,"indication":"Non Small Cell Lung Carcinoma","completionDate":"2007-01"},{"nctId":"NCT00445549","phase":"Phase 2","title":"Phase II Study of Clinical Activity and Proteomic Pathway Profiling of the Vascular Endothelial Growth Factor 2 (VEGFR2) Inhibitor, ZD6474 (Vandetanib) in Women With Relapsed or Refractory Epithelial ","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","isPivotal":false,"enrollment":12,"indication":"Ovarian Neoplasms, Fallopian Tube Neoplasms","completionDate":"2009-10"},{"nctId":"NCT00822887","phase":"Phase 1","title":"A Phase I Dose Escalation Study of Vandetanib (ZACTIMA, ZD6474) With Hypofractionated Stereotactic Radiotherapy in Patients With Recurrent Malignant Gliomas","status":"COMPLETED","sponsor":"University of Colorado, Denver","isPivotal":false,"enrollment":13,"indication":"Malignant Gliomas","completionDate":"2011-01"},{"nctId":"NCT00777179","phase":"Phase 2","title":"Randomized, Double-blinded, Placebo-controlled Phase II Study of Vandetanib (ZactimaTM) Maintenance for Locally Advanced or Metastatic Non-small-cell Lung Carcinoma (NSCLC) Following Platinum-doublet ","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","isPivotal":false,"enrollment":117,"indication":"NSCLC","completionDate":"2011-12"},{"nctId":"NCT01183559","phase":"Phase 1","title":"Induction Therapy for Locally Advanced, Resectable Cancer of the Esophagus, Gastroesophageal (GE) Junction and Gastric Cancer: A Phase I Trial of ZD6474 (Zactima, Vandetanib), Paclitaxel, Carboplatin,","status":"COMPLETED","sponsor":"Fox Chase Cancer Center","isPivotal":false,"enrollment":9,"indication":"Cancer of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction","completionDate":"2011-08"},{"nctId":"NCT00566995","phase":"Phase 2","title":"A Phase 2 Study of ZD6474 (Vandetanib) in Patients With Von Hippel Lindau Disease and Renal Tumors","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","isPivotal":false,"enrollment":37,"indication":"Renal Cancer, Von Hippel Lindau","completionDate":"2015-03"},{"nctId":"NCT00496509","phase":"Phase 1","title":"A Phase I, Open-Label Study To Assess The Effect of ZD6474 (ZACTIMA) On Vascular Permeability In Patients With Advanced Colorectal Cancer and Liver Metastases","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","isPivotal":false,"enrollment":24,"indication":"Colorectal Cancer","completionDate":"2007-10"},{"nctId":"NCT00472017","phase":"Phase 1","title":"Phase I Trial of Vandetanib (ZD6474, ZACTIMA) With Concurrent Radiation in Treatment of Newly Diagnosed Brainstem Glioma","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","isPivotal":false,"enrollment":35,"indication":"Brain and Central Nervous System Tumors","completionDate":"2011-10"},{"nctId":"NCT00681798","phase":"Phase 1","title":"Dose Escalation Study of the Combination of ZD6474, Gemcitabine and Capecitabine in Locally Advanced Unresectable or Metastatic Pancreatic Adenocarcinoma","status":"COMPLETED","sponsor":"Sanofi","isPivotal":false,"enrollment":8,"indication":"Pancreatic Cancer","completionDate":"2009-06"},{"nctId":"NCT00496665","phase":"Phase 1","title":"A Phase I Study of ZD6474 (Zactima) and Metronomic Chemotherapy in Advanced Breast Cancer","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","isPivotal":false,"enrollment":25,"indication":"Metastatic Breast Cancer","completionDate":"2009-03"},{"nctId":"NCT00613223","phase":"Phase 1","title":"Phase I Dose Escalation of Vandetanib (Zactima, ZD6474) in Combination With Etoposide for Malignant Gliomas","status":"COMPLETED","sponsor":"Annick Desjardins","isPivotal":false,"enrollment":49,"indication":"Gliosarcoma, Glioblastoma","completionDate":"2011-05"},{"nctId":"NCT00358956","phase":"Phase 2","title":"A Phase II, Open-Label Study To Assess The Efficacy and Tolerability of ZD6474 (ZACTIMA™ ) 100 mg Monotherapy In Subjects With Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","isPivotal":false,"enrollment":19,"indication":"Thyroid Cancer","completionDate":"2014-05"},{"nctId":"NCT02530411","phase":"Phase 2","title":"A Randomised Double Blind Placebo Controlled Phase II Study of Fulvestrant With or Without the Addition of Vandetanib as Treatment for Patients With Metastatic Breast Cancer Resistant to Aromatase Inh","status":"UNKNOWN","sponsor":"Velindre NHS Trust","isPivotal":false,"enrollment":160,"indication":"Neoplasms","completionDate":"2020-12"},{"nctId":"NCT01582191","phase":"Phase 1","title":"A Phase 1 Trial of Vandetanib (a Multi-Kinase Inhibitor of EGFR, VEGFR, and RET Inhibitor) in Combination With Everolimus (an mTOR Inhibitor) in Advanced Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","isPivotal":false,"enrollment":151,"indication":"Advanced Malignant Neoplasm, Metastatic Malignant Neoplasm","completionDate":"2025-10-22"},{"nctId":"NCT00410761","phase":"Phase 3","title":"An International, Phase III, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study to Assess the Efficacy of ZD6474 (ZACTIMATM) Versus Placebo in Subjects With Unresectable Locally Advanc","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","isPivotal":true,"enrollment":331,"indication":"Thyroid Cancer","completionDate":"2024-07-26"},{"nctId":"NCT00364351","phase":"Phase 3","title":"A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","isPivotal":true,"enrollment":1574,"indication":"Non Small Cell Lung Cancer","completionDate":"2016-11"},{"nctId":"NCT00613054","phase":"Phase 1","title":"Phase I Study of Zactima (ZD6474) Plus Imatinib Mesylate and Hydroxyurea for Patients With Recurrent Malignant Glioma","status":"COMPLETED","sponsor":"Annick Desjardins","isPivotal":false,"enrollment":27,"indication":"Glioblastoma, Gliosarcoma","completionDate":"2009-04"},{"nctId":"NCT00459043","phase":"Phase 2","title":"Randomized Phase II Study of Docetaxel in Combination With Zactima (ZD6474) in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","isPivotal":false,"enrollment":30,"indication":"Squamous Cell Carcinoma of Head and Neck","completionDate":"2012-02"},{"nctId":"NCT01004419","phase":"Phase 1","title":"Phase I Trial of Vandetanib (ZD6474, Zactima) and Fulvestrant (Faslodex) as Third-Line Treatment of Advanced Non-Small Cell Lung Cancer","status":"WITHDRAWN","sponsor":"University of Wisconsin, Madison","isPivotal":false,"enrollment":0,"indication":"Carcinoma, Non Small Cell Lung","completionDate":"2011-05"},{"nctId":"NCT00862836","phase":"Phase 1","title":"Addition of Vandetanib to Standard Therapy (Pegliposomal Doxorubicin) in Patients With Recurrent Ovarian Cancer. A Multicentre Phase I / Randomized Phase II Study","status":"TERMINATED","sponsor":"Genzyme, a Sanofi Company","isPivotal":false,"enrollment":15,"indication":"Ovarian Cancer","completionDate":"2010-09"},{"nctId":"NCT00745732","phase":"Phase 1","title":"A Phase I Dose-Escalation and Safety Study of ZD6474 (ZACTIMA) Used In Combination With Radiation Therapy for Patients With Inoperable/Unresectable Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","isPivotal":false,"enrollment":3,"indication":"Non-Small Cell Lung Cancer","completionDate":"2012-09"},{"nctId":"NCT00807170","phase":"Phase 1","title":"A Phase I Study of ZD6474 (Vandetanib) Concurrent With Whole Brain Radiotherapy for the Treatment of Brain Metastases in Patients With Non-small Cell Lung Cancer (NSCLC)","status":"TERMINATED","sponsor":"Sanofi","isPivotal":false,"enrollment":5,"indication":"Non-small Cell Lung Cancer (NSCLC)","completionDate":"2010-08"},{"nctId":"NCT00507091","phase":"Phase 1","title":"A Phase I Open Label Study to Asses the Safety and Tolerability of ZD6474 (Vandetanib)in Combination With Irinotecan, 5-Fluorouracil and Leucovorin (FOLFIRI) as First or Second Line Therapy in Patient","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","isPivotal":false,"enrollment":24,"indication":"Metastatic, Colorectal","completionDate":"2008-06"},{"nctId":"NCT00494481","phase":"Phase 2","title":"A Phase II, Double-blind, Placebo Controlled, Randomized Study to Assess the Efficacy and Safety of ZD6474 in Combination With Docetaxel (Taxotere™) vs Docetaxel Alone as 2nd Line Treatment for Advanc","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","isPivotal":false,"enrollment":64,"indication":"Advanced Breast Cancer","completionDate":"2009-01"},{"nctId":"NCT00551096","phase":"Phase 1","title":"A Phase I Study of Gemcitabine, Capecitabine and ZD6474 (ZACTIMA) in Patients With Advanced Solid Tumors With an Expanded Cohort of Patients With Biliary or Pancreatic Malignancies.","status":"COMPLETED","sponsor":"University of Colorado, Denver","isPivotal":false,"enrollment":23,"indication":"Malignant Solid Tumour, Biliary Cancer","completionDate":"2013-05"},{"nctId":"NCT00506051","phase":"Phase 1","title":"A Phase I, Open-Label Study to Assess the Safety and Tolerability of ZD6474 in Combination With Pemetrexed (Alimta) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer After Fai","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","isPivotal":false,"enrollment":21,"indication":"Carcinoma, Non-Small Cell Lung","completionDate":"2011-10"},{"nctId":"NCT00686036","phase":"Phase 2","title":"A Randomized, Double-blind, Multicentre, Phase II Controlled Trial Assessing ZACTIMATM (Vandetanib) Against Placebo in Prolonging the Off-treatment Interval in Prostate Cancer Subjects Undergoing Inte","status":"TERMINATED","sponsor":"Genzyme, a Sanofi Company","isPivotal":false,"enrollment":17,"indication":"Prostate Cancer","completionDate":"2010-10"},{"nctId":"NCT00659438","phase":"Phase 2","title":"A Randomized, Double-blind Phase II Trial to Assess the Efficacy and Safety of Bicalutamide (Casodex® ) Associated to ZD6474 (Zactima™ ) or to Placebo in Patients With Castration-refractory Metastatic","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","isPivotal":false,"enrollment":95,"indication":"Prostate Cancer","completionDate":"2011-07"},{"nctId":"NCT00454116","phase":"Phase 2","title":"A Phase II, Double Blind, Placebo Controlled, Randomised Study to Assess the Efficacy and Safety of 2 Doses of ZACTIMA™(ZD6474) in Combination With FOLFIRI vs FOLFIRI Alone for the Treatment of Colore","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","isPivotal":false,"enrollment":106,"indication":"Colorectal Cancer","completionDate":"2009-11"},{"nctId":"NCT00459121","phase":"Phase 2","title":"Assessment of Feasibility and Safety of the Addition of ZD6474 (Zactima) to Carboplatin and Paclitaxel Administered Neo-Adjuvantly in Stage IB, II and T3, N1 Non-Small Cell Lung Cancer (NSCLC)","status":"TERMINATED","sponsor":"Barbara Ann Karmanos Cancer Institute","isPivotal":false,"enrollment":2,"indication":"Lung Cancer","completionDate":"2008-10"},{"nctId":"NCT00503711","phase":"Phase 1","title":"An Open Label, Phase I, Rising Multiple Dose, Single Centre Study to Determine the PK and Tolerability of ZD6474 at Different Dose Levels in Chinese Patients With Solid Malignancy Tumor","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","isPivotal":false,"enrollment":36,"indication":"Advanced Solid, Malignant Tumors","completionDate":"2007-11"},{"nctId":"NCT00441142","phase":"Phase 1","title":"Phase I/II Study of ZD6474 (Vandetanib) With Radiation Therapy and Concomitant and Adjuvant Temozolomide in Patients With Newly-Diagnosed Glioblastoma","status":"COMPLETED","sponsor":"Patrick Y. Wen, MD","isPivotal":false,"enrollment":119,"indication":"Glioblastoma Multiforme, Gliosarcoma","completionDate":"2017-10-10"},{"nctId":"NCT00498797","phase":"Phase 2","title":"A Phase II, Double-blind, Placebo-controlled, Randomised Study to Assess the Efficacy and Safety of Docetaxel (Taxotere)/Prednisolone/ZD6474 vs Docetaxel/Prednisolone/Placebo in Patients With Hormone ","status":"COMPLETED","sponsor":"Sanofi","isPivotal":false,"enrollment":86,"indication":"Prostate Cancer, Metastatic","completionDate":"2008-09"},{"nctId":"NCT00597116","phase":"Phase 2","title":"A Randomized Phase II Trial To Evaluate The Efficacy And Safety Of Vandetanib (ZD6474, ZACTIMA ™) Versus Vinorelbine In Patients With Inoperable Or Relapsed Malignant Mesothelioma.","status":"TERMINATED","sponsor":"Genzyme, a Sanofi Company","isPivotal":false,"enrollment":25,"indication":"Mesothelioma","completionDate":"2010-01"},{"nctId":"NCT00499850","phase":"Phase 1","title":"A Phase I,Open Label Study to Assess the Safety and Tolerability of ZD6474 in Combination With 5-Fluorouracil, Leucovorin and Oxaliplatin (mFOLFOX6) as First and Second Line Therapy in Patients With A","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","isPivotal":false,"enrollment":18,"indication":"Advanced Colorectal Carcinoma","completionDate":"2008-04"},{"nctId":"NCT00880334","phase":"Phase 2","title":"Randomized Study of Docetaxel +/- Vandetanib in Metastatic TCC","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","isPivotal":false,"enrollment":149,"indication":"Transitional Cell Carcinoma, Bladder Cancer","completionDate":"2015-05"},{"nctId":"NCT00514046","phase":"Phase 1","title":"Phase I/II Trial of Vandetanib (ZD6474, ZACTIMA) in Children and Adolescents With Hereditary Medullary Thyroid Carcinoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","isPivotal":false,"enrollment":17,"indication":"Medullary Thyroid Carcinoma, Multiple Endocrine Neoplasia Type 2A","completionDate":"2020-11-01"},{"nctId":"NCT00923247","phase":"Phase 1","title":"A Targeted Ph I/II Trial of ZD6474 (Vandetanib; CAPRELSA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or ","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","isPivotal":false,"enrollment":22,"indication":"Medullary Thyroid Carcinoma","completionDate":"2016-12-09"},{"nctId":"NCT00660725","phase":"Phase 1","title":"An Open Label Phase I Study of Gemcitabine/Oxaliplatin (GEMOX) and Vandetanib (ZACTIMA; ZD6474) Combination in Patients With Advanced Solid Malignancy (IRUSZACT0070) (UPCI 07-025)","status":"COMPLETED","sponsor":"Leonard Appleman","isPivotal":false,"enrollment":22,"indication":"Advanced Incurable Solid Malignancy","completionDate":"2010-12"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"","frequency":"","formulation":""},"formularyStatus":[],"apiManufacturers":[],"developmentCodes":[],"ownershipHistory":[],"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"firstApprovalDate":"","companionDiagnostics":[],"firstApprovalCountry":null,"genericManufacturerList":[],"modality":"Small molecule","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":2},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}